Alert detail
FDA Approval: LEQSELVI (DEURUXOLITINIB PHOSPHATE) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA217900Specialty: DermatologyAdded: 7/8/2026Effective: 2024-07-25federal register
What changed
Oral Leqselvi routes to Part D; no J-code applies.
Who’s affected: Dermatology billing teams · Effective: 2024-07-25
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Not ready to subscribe?
Get the free weekly reimbursement brief for Dermatology— the week’s changes and deadlines, delivered to your inbox. No account required.